News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Faga Daniel
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/10/2023 |
4
| Faga Daniel (Interim CEO) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 194,900 options to buy
@ $23.23, valued at
$4.5M
Granted 71,400 restricted stock units
@ $0 |
|
| 03/23/2022 |
4
| Faga Daniel (Interim CEO) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 887,043 shares
@ $0 |
|
| 02/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2021 |
4
| Faga Daniel (Director) has filed a Form 4 on ANAPTYSBIO, INC|
Txns:
| Granted 11,000 options to buy
@ $31.12, valued at
$342.3k
Granted 2,321 options to buy
@ $31.12, valued at
$72.2k
|
|
| 11/30/2021 |
3
| Faga Daniel (Director) has filed a Form 3 on ANAPTYSBIO, INC |
| 02/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/08/2020 |
4
| Faga Daniel (EVP, COO) has filed a Form 4 on Mirati Therapeutics, Inc.|
Txns:
| Granted 26,240 shares
@ $0
Granted 64,970 options to buy
@ $114.33, valued at
$7.4M
|
|
| 01/08/2020 |
3
| Faga Daniel (EVP, COO) has filed a Form 3 on Mirati Therapeutics, Inc. |
| 12/17/2019 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Unknown transaction of 38,828 shares
@ $114.5, valued at
$4.4M
Disposed/sold 35,000 options to buy
@ $42.73, valued at
$1.5M
Disposed/sold 26,250 options to buy
@ $50.55, valued at
$1.3M
Disposed/sold 14,000 options to buy
@ $56.17, valued at
$786.4k
Disposed/sold 50,000 options to buy
@ $37.62, valued at
$1.9M
Disposed/sold 21,500 restricted stock units
@ $0 |
|
| 03/27/2019 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 51,401 shares
@ $113.42, valued at
$5.8M
Paid exercise price by delivering 10,325 shares
@ $113.43, valued at
$1.2M
Paid exercise price by delivering 6,228 shares
@ $113.43, valued at
$706.4k
Exercised 80,000 options to buy
@ $37.62, valued at
$3M
Exercised 14,000 options to buy
@ $56.17, valued at
$786.4k
Exercised 8,750 options to buy
@ $50.55, valued at
$442.3k
|
|
| 01/23/2019 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 766 shares
@ $45.08, valued at
$34.5k
Paid exercise price by delivering 823 shares
@ $45.08, valued at
$37.1k
Exercised 2,000 restricted stock units
@ $0
Exercised 2,500 restricted stock units
@ $0 |
|
| 01/17/2019 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $42.73, valued at
$1.5M
Granted 10,000 restricted stock units
@ $0 |
|
| 01/22/2018 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 879 shares
@ $50.55, valued at
$44.4k
Granted 35,000 options to buy
@ $50.55, valued at
$1.8M
Granted 10,000 restricted stock units
@ $0
Exercised 2,000 restricted stock units
@ $0 |
|
| 10/24/2017 |
4
| Faga Daniel (Chief Business Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 6,000 shares
@ $79.95, valued at
$479.7k
Sold 1,500 shares
@ $85, valued at
$127.5k
Exercised 6,000 options to buy
@ $37.62, valued at
$225.7k
Exercised 1,500 options to buy
@ $37.62, valued at
$56.4k
|
|
| 09/20/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/14/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/11/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/26/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/20/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|